Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
24-Jun-2021
Manufacturing patents granted for paxalisib
21-Jun-2021
Ceasing to be a substantial holder
15-Jun-2021
Kazia launches new paxalisib phase II clinical trial
7-Jun-2021
Kazia paxalisib in Dana Farber study enrols first patient
2-Jun-2021
Appendix 3Y for 3 directors
27-May-2021
Change in substantial holding
21-May-2021
Appendix 2A
10-May-2021
Change in substantial holding
4-May-2021
Change of directors interests * 3
30-Apr-2021
Cleansing notice
Previous
1
2
3
4
5
6
7
Next
